PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that preclinical data from several investigational antibody-drug conjugate candidates in development, each in separate studies, demonstrated enhanced anti-tumor activity in xenograft models when compared to the anti-cancer antibodies alone. The use of antibody- drug conjugate candidates is another new strategy to fight cancer by targeting molecules implicated in disease (including B7-H4, prostate-specific membrane antigen, mindin/RG1, CD70 and Ptk7) with antibodies linked to cytotoxic agents that are designed to kill cancer cells. Results from the preclinical studies were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.
“Our research and expertise in the antibody field continues to broaden our pipeline with potentially important anti-cancer agents,” said Howard H. Pien, President and CEO of Medarex. “We are encouraged by the single-dose efficacy observed in animal models from our antibody-drug conjugate technology platform, and remain on track to prepare for our first antibody-drug conjugate candidate IND filing this year.”
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed herein relating to the preclinical data on multiple antibody-drug conjugate candidates may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words “potential"; “may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward- looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex’s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex’s public disclosure filings are available from its investor relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x2216, or
Nichol Harber, Corporate Communications (media), +1-609-430-2880, x2214, or
Jean Mantuano, Corporate Communications (media), +1-609-430-2880, x2221
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html/
